A simplified disease activity index for rheumatoid arthritis for use in clinical practice von Smolen, J. S., Breedveld, F. C., Schiff, M. H., Kalden, J. R., Emery, P., Eberl, G., van Riel, P. L., Tugwell, P.

Volltext

Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of rem... von Smolen, J S, Han, C, van der Heijde, D M F M, Emery, P, Bathon, J M, Keystone, E, Maini, R N, Kalden, J R, Aletaha, D, Baker, D, Han, J, Bala, M, St Clair, E W

Volltext

Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide von Emery, P, Breedveld, F C, Dougados, M, Kalden, J R, Schiff, M H, Smolen, J S

Volltext

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of... von Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J

Volltext

Infliximab in active early rheumatoid arthritis von Breedveld, F C, Emery, P, Keystone, E, Patel, K, Furst, D E, Kalden, J R, St Clair, E W, Weisman, M, Smolen, J, Lipsky, P E, Maini, R N

Volltext

Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis... von Fransen, J, Antoni, C, Mease, P J, Uter, W, Kavanaugh, A, Kalden, J R, Van Riel, P L C M

Volltext

Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus von Manger, K, Manger, B, Repp, R, Geisselbrecht, M, Geiger, A, Pfahlberg, A, Harrer, T, Kalden, J R

Volltext

EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees von Dougados, M, Betteridge, N, Burmester, G R, Euller-Ziegler, L, Guillemin, F, Hirvonen, J, Lloyd, J, Ozen, S, Da Silva, J A P, Emery, P, Kalden, J R, Kvien, T, Matucci-Cerinic, M, Smolen, J

Volltext

Autoantibody profiles in the sera of European patients with myositis von Brouwer, R, Hengstman, G J D, Egberts, W Vree, Ehrfeld, H, Bozic, B, Ghirardello, A, Grøndal, G, Hietarinta, M, Isenberg, D, Kalden, J R, Lundberg, I, Moutsopoulos, H, Roux-Lombard, P, Vencovsky, J, Wikman, A, Seelig, H P, van Engelen, B G M, van Venrooij, W J

Volltext

Appropriate and effective management of rheumatoid arthritis von Breedveld, F C, Kalden, J R

Volltext

Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase... von van de Putte, L B A, Rau, R, Breedveld, F C, Kalden, J R, Malaise, M G, van Riel, P L C M, Schattenkirchner, M, Emery, P, Burmester, G R, Zeidler, H, Moutsopoulos, H M, Beck, K, Kupper, H

Volltext

Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of... von Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Bijlsma, J W J, Dougados, M, Emery, P, Keystone, E C, Klareskog, L, Mease, P J

Volltext

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006 von Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Emery, P, Keystone, E C, Schiff, M H, van Riel, P L C M, Weinblatt, M E, Weisman, M H

Volltext

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis von Elliott, M.J, Maini, R.N, Feldmann, M, Kalden, J.R, Antoni, C, Smolen, J.S, Leeb, B, Breedveld, F.C, Macfarlane, J.D, Bijl, J.A, Woody, J.N

Volltext

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine von Scott, D L, Smolen, J S, Kalden, J R, van de Putte, L B A, Larsen, A, Kvien, T K, Schattenkirchner, M, Nash, P, Oed, C, Loew-Friedrich, I

Volltext

Factors associated with coronary artery calcification in young female patients with SLE von Manger, K, Kusus, M, Forster, C, Ropers, D, Daniel, W G, Kalden, J R, Achenbach, S, Manger, B

Volltext

Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences von Kraetsch, H G, Antoni, C, Kalden, J R, Manger, B

Volltext

Distinct tumour necrosis factor α, interferon γ, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener’s gr... von Spriewald, B M, Witzke, O, Wassmuth, R, Wenzel, R R, Arnold, M-L, Philipp, T, Kalden, J R

Volltext

IgG autoantibodies bound to surfaces of necrotic cells and complement C4 comprise the phagocytosis promoting activity for necrotic cells of systemic lupus erythaematosus sera von Grossmayer, G E, Munoz, L E, Weber, C K, Franz, S, Voll, R E, Kern, P M, Kalden, J R, Schett, G, Herrmann, M, Gaipl, U S

Volltext

Advances in targeted therapies X von Breedveld, F C, Kalden, J R, Smolen, J S

Volltext